To be or not to be a case of heparin resistance

被引:34
作者
Durrani, Jibran [1 ]
Malik, Faizan [1 ]
Ali, Naveed [1 ]
Jafri, Syed Imran Mustafa [1 ]
机构
[1] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA
关键词
Activated partial thromboplastin time (aPTT); anti-thrombin III (ATIII); activated coagulation time (ACT); unfractionated heparin(UFH); low molecular weight heparin(LMWH); anti-factor 10a (AF 10a); pulmonary embolism (PE); disseminated intravascular coagulation (DIC);
D O I
10.1080/20009666.2018.1466599
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin resistance can be defined as high doses of unfractionated heparin (UFH), greater than 35,000 IU/day, required to raise the activated partial thromboplastin time (aPTT) and activated coagulation time (ACT) to within therapeutically desired ranges or the impossibility of doing so. The most common pathology responsible is the deficiency of anti-thrombin III (ATIII) deficiency. Other clinically relevant conditions that can present with heparin resistance are congenital deficiencies; use of high doses of heparin during extracorporeal circulation, use of asparaginase therapy and disseminated intravascular coagulation (DIC). Most of these conditions effect the ATIII levels. Patients are typically identified in an acute phase, when determination of the cause of resistance is challenging. We present a case where a patient presented with suspected heparin resistance in an acute phase of sickness, where timely intervention was able to prevent a potentially fatal situation.
引用
收藏
页码:145 / 148
页数:4
相关论文
共 21 条
[1]  
BOCK SC, 1985, AM J HUM GENET, V37, P32
[2]   ANTITHROMBIN-III UTAH - PROLINE-407 TO LEUCINE MUTATION IN A HIGHLY CONSERVED REGION NEAR THE INHIBITOR REACTIVE SITE [J].
BOCK, SC ;
MARRINAN, JA ;
RADZIEJEWSKA, E .
BIOCHEMISTRY, 1988, 27 (16) :6171-6178
[3]  
BOCK SC, 1989, THROMB HAEMOSTASIS, V62, P494
[4]  
CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392
[5]  
Cirisano FD, 1996, J REPROD MED, V41, P191
[6]   Advances in understanding pathogenic mechanisms of thrombophilic disorders [J].
Dahlback, Bjorn .
BLOOD, 2008, 112 (01) :19-27
[7]   Monitoring unfractionated heparin with the aPTT: Time for a fresh look [J].
Eikelboom, John W. ;
Hirsh, Jack .
THROMBOSIS AND HAEMOSTASIS, 2006, 96 (05) :547-552
[8]   Impaired cotranslational processing as a mechanism for type I antithrombin deficiency [J].
Fitches, AC ;
Appleby, R ;
Lane, DA ;
De Stefano, V ;
Leone, G ;
Olds, RJ .
BLOOD, 1998, 92 (12) :4671-4676
[9]   Mechanism of action and pharmacology of unfractionated heparin [J].
Hirsh, J ;
Anand, SS ;
Halperin, JL ;
Fuster, V .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (07) :1094-1096
[10]  
HULTIN MB, 1988, THROMB HAEMOSTASIS, V59, P468